Diagnostic and Prognostic Values of Soluble Suppression of Tumorigenicity-2 Measurements in the Treatment Assessment of Adult Patients with Congenital Heart Disease and Cardiac Failure

Zahra Khajali; Ata  Firouzi; Maedeh Arabian; Nasim Naderi; Majid  Maleki; Sedigheh Saedi; Maryam Aliramezany

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Reviewer and AE Registration Form Support Contact Us

APC

Authors Guide Submit Manuscript

Diagnostic and Prognostic Values of Soluble Suppression of Tumorigenicity-2 Measurements in the Treatment Assessment of Adult Patients with Congenital Heart Disease and Cardiac Failure

Author(s):

Zahra Khajali

¹,

Ata Firouzi

¹,

Maedeh Arabian

¹,

Nasim Naderi

¹,

Majid Maleki

¹,

Sedigheh Saedi

¹,

Maryam Aliramezany

^2,*

1Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran

2Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, IR Iran

International Cardiovascular Research Journal:Vol. 14, issue 4; e109763

Published online:Dec 15, 2020

Article type:Research Article

Received:Sep 25, 2020

Accepted:Dec 07, 2020

How to Cite:Zahra Khajali, Ata Firouzi, Maedeh Arabian, Nasim Naderi, Majid Maleki, et al. Diagnostic and Prognostic Values of Soluble Suppression of Tumorigenicity-2 Measurements in the Treatment Assessment of Adult Patients with Congenital Heart Disease and Cardiac Failure.Int Cardiovasc Res J.2020;14(4):e109763.

Abstract

Background:
The standard heart failure treatment in adult patients with Congenital Heart Disease (CHD) is a challenging issue. Biomarkers, such as N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP), have been used, but soluble Suppression of Tumorigenicity-2 (sST2) has been able to bring prognostic value in patients with acute and chronic left heart failure.
Objectives:
The present study sought to evaluate the predictive value of sST2 and NT-proBNP measurements in the assessment of the efficacy of treatment of adult patients with symptomatic CHD.
Methods:
This case series was conducted using a before/after design on 80 consecutive adult patients with CHD who had never received treatment for symptomatic heart failure (New York Heart Association functional classes II, III). sST2 levels were measured before and six months after the standard drug regimen of cardiac dysfunction according to the American guidelines in order to assess the efficacy of the standard treatment on sST2. Cardiac function was assessed via echocardiography and functional capacity via the 6-Minute Walk Test (6MWT) and direct inquiry from the patients before and six months after the treatment. The data were entered into the SPSS 22 software and were analyzed using paired t-test, Wilcoxon, and chi-square test.
Results:
The mean age of the patients was 32 years. At the six-month follow-up, functional capacity showed a significant improvement based on the mean 6MWT compared to the pre-treatment state (P < 0.001). In addition, the standard treatment significantly decreased the sST2 level compared to the pre-treatment value (P < 0.001).
Conclusions:
The measurement of biomarkers could help assess the efficacy of the treatment of adult patients with CHD and symptomatic heart failure.

Keywords

Congenital Heart Disease

NT-proBNP

ST2

Fulltext

The full-text is available in pdf.

References

1.
The references are available in pdf.

comments